Construction of first- and second-generation drug-eluting stents (DES) and proposed pathophysiological mechanism of late adverse events
| Construction | Mechanism | |
|---|---|---|
| First-generation DES | Thick struts Uneven polymer distribution with poor integrity and thick coating of durable polymers High drug dose | Uncovered struts Hypersensitivity Malapposition from fibrin deposition Stent fracture Neoatherosclerosis (especially for second-generation DES) |
| Second-generation DES | Thinner struts More biocompatible polymer (durable) Reduced drug dose |